LadRx Corporation (CYTR)

$0.09

0.00 (-%)
Rating:
Recommendation:
Neutral
Symbol CYTR
Price $0.09
Beta 2.101
Volume Avg. 0.06M
Market Cap 4.143M
Shares () -
52 Week Range 0.0521-0.86
1y Target Est -
DCF Unlevered CYTR DCF ->
DCF Levered CYTR LDCF ->
ROE -210.77% Strong Sell
ROA -254.62% Strong Sell
Operating Margin -
Debt / Equity 120.27% Buy
P/E -
P/B 1.75 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Steven Kriegsman
Healthcare
Biotechnology
Other OTC

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.